Gene signature of circulating platelet-bound neutrophils is associated with poor prognosis in cancer patients.

cancer low-density-neutrophils neutrophil-platelet aggregates neutrophils platelets

Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 07 2022
Historique:
revised: 08 02 2022
received: 26 08 2021
accepted: 17 02 2022
pubmed: 8 3 2022
medline: 18 5 2022
entrez: 7 3 2022
Statut: ppublish

Résumé

Beyond their critical role in hemostasis, platelets physically interact with neutrophils to form neutrophil-platelet aggregates (NPAs), enhancing neutrophil effector functions during inflammation. NPAs may also promote disease worsening in various inflammatory diseases. However, characterization of NPAs in cancer remains totally unexplored. Using ImageStreamX (ISX) imaging flow cytometer, we were not only allowed able to detect CD15

Identifiants

pubmed: 35253899
doi: 10.1002/ijc.33991
pmc: PMC9311065
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

138-152

Informations de copyright

© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

J Immunother Cancer. 2018 Jul 16;6(1):74
pubmed: 30012216
Sci Immunol. 2019 Oct 18;4(40):
pubmed: 31628161
Genome Med. 2021 Jan 13;13(1):7
pubmed: 33441124
J Thromb Haemost. 2011 Apr;9(4):799-809
pubmed: 21251195
Cancer Cell. 2016 Jul 11;30(1):120-135
pubmed: 27374224
Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2392-9
pubmed: 21071696
Surg Oncol. 2014 Mar;23(1):31-9
pubmed: 24378193
Front Immunol. 2019 Sep 20;10:2155
pubmed: 31616408
J Immunother Cancer. 2018 Nov 23;6(1):129
pubmed: 30470260
J Transl Med. 2014 Mar 11;12:65
pubmed: 24612859
Sci Immunol. 2016 Aug;1(2):
pubmed: 28417112
Science. 2018 Sep 28;361(6409):
pubmed: 30262472
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Thromb Haemost. 2012 Oct;108(4):719-29
pubmed: 22836389
Int J Cancer. 2011 Nov 1;129(9):2183-93
pubmed: 21190185
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
Science. 2014 Dec 5;346(6214):1234-8
pubmed: 25477463
World J Surg Oncol. 2016 May 16;14:148
pubmed: 27184053
Eur J Cancer. 2018 Jan;89:56-63
pubmed: 29227818
Sci Transl Med. 2018 Apr 4;10(435):
pubmed: 29618559
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Br J Haematol. 1999 Aug;106(2):391-9
pubmed: 10460597
Am J Physiol Heart Circ Physiol. 2011 Feb;300(2):H468-75
pubmed: 21169400
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16481-16491
pubmed: 32601182
Clin Cancer Res. 2018 Oct 1;24(19):4834-4844
pubmed: 29914893
Lung Cancer. 2017 Sep;111:176-181
pubmed: 28838390
Front Immunol. 2019 Aug 16;10:1867
pubmed: 31474979
Sci Adv. 2020 Mar 11;6(11):eaaz1580
pubmed: 32195350
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Gut. 2018 Jun;67(6):1112-1123
pubmed: 29196437
Microbiol Spectr. 2016 Oct;4(5):
pubmed: 27763252
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Cell Rep. 2015 Feb 3;10(4):562-73
pubmed: 25620698
Blood. 2020 Sep 10;136(11):1317-1329
pubmed: 32573711
Cell Syst. 2019 Apr 24;8(4):281-291.e9
pubmed: 30954476
Nature. 2015 Jun 18;522(7556):345-348
pubmed: 25822788
Cancer Cell. 2015 Dec 14;28(6):785-799
pubmed: 26678340
Gastroenterology. 2016 Jun;150(7):1646-1658.e17
pubmed: 26924089
Cell. 2019 Jul 11;178(2):346-360.e24
pubmed: 31257026
Nature. 2015 Dec 17;528(7582):413-7
pubmed: 26649828
Nat Med. 2007 Apr;13(4):463-9
pubmed: 17384648
J Clin Invest. 2012 Jul;122(7):2661-71
pubmed: 22684106
J Leukoc Biol. 2016 May;99(5):781-9
pubmed: 26578648
Thromb Haemost. 2020 Dec;120(12):1733-1735
pubmed: 33124027
Circulation. 2007 Mar 27;115(12):1551-62
pubmed: 17353439
FASEB J. 2020 Mar;34(3):4204-4218
pubmed: 31957112
Cancer Res. 2009 Feb 15;69(4):1553-60
pubmed: 19201693
Science. 2017 Dec 1;358(6367):
pubmed: 29191879
Infect Immun. 2015 Sep;83(9):3515-25
pubmed: 26099589
J Immunol. 2009 May 15;182(10):6527-32
pubmed: 19414807
Circ J. 2015;79(6):1349-56
pubmed: 25787672
J Clin Invest. 2018 Aug 1;128(8):3425-3438
pubmed: 29771686
Cancer Res. 2004 Aug 15;64(16):5839-49
pubmed: 15313928
F1000Res. 2020 Apr 1;9:223
pubmed: 32765839
PLoS One. 2018 Oct 10;13(10):e0204490
pubmed: 30304046
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
PLoS One. 2018 Apr 6;13(4):e0195042
pubmed: 29624591
Int J Cancer. 2022 Jul 1;151(1):138-152
pubmed: 35253899
Cell Host Microbe. 2012 Sep 13;12(3):324-33
pubmed: 22980329
Nat Commun. 2017 Apr 18;8:14780
pubmed: 28416795

Auteurs

Pacôme Lecot (P)

TERI (Tumor Escape, Resistance and Immunity) Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.

Maude Ardin (M)

TERI (Tumor Escape, Resistance and Immunity) Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.

Sébastien Dussurgey (S)

Université de Lyon, SFR Biosciences, ENS de Lyon, Inserm US8, CNRS UMS3444, Lyon, France.

Vincent Alcazer (V)

TERI (Tumor Escape, Resistance and Immunity) Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.

Lyvia Moudombi (L)

TERI (Tumor Escape, Resistance and Immunity) Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.

Manuela Pereira Abrantes (M)

TERI (Tumor Escape, Resistance and Immunity) Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.

Margaux Hubert (M)

TERI (Tumor Escape, Resistance and Immunity) Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.

Aurélie Swalduz (A)

Department of Lung and Thoracic Medical Oncology, Centre Léon Bérard, Lyon, France.

Hector Hernandez-Vargas (H)

TERI (Tumor Escape, Resistance and Immunity) Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.

Alain Viari (A)

Synergie Lyon Cancer, Plateforme de Bio-informatique 'Gilles Thomas', Lyon, France.

Christophe Caux (C)

TERI (Tumor Escape, Resistance and Immunity) Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.

Marie-Cécile Michallet (MC)

TERI (Tumor Escape, Resistance and Immunity) Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH